PMID- 23579060
OWN - NLM
STAT- MEDLINE
DCOM- 20131104
LR  - 20130412
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 15
IP  - 3
DP  - 2013 Mar
TI  - Induction of potent protection against acute and latent herpes simplex virus 
      infection in mice vaccinated with dendritic cells.
PG  - 352-61
LID - S1465-3249(12)00041-2 [pii]
LID - 10.1016/j.jcyt.2012.11.012 [doi]
AB  - BACKGROUND AIMS: Dendritic cells (DCs) are the most potent antigen presenting 
      cells of the immune system and have been under intense study with regard to their 
      use in immunotherapy against cancer and infectious disease agents. In the present 
      study, DCs were employed to assess their value in protection against live virus 
      challenge in an experimental model using lethal and latent herpes simplex virus 
      (HSV) infection in Balb/c mice. METHODS: DCs obtained ex vivo in the presence of 
      granulocyte-macrophage colony-stimulating factor and interleukin-4 were loaded 
      with HSV-1 proteins (DC/HSV-1 vaccine). Groups of mice were vaccinated twice, 7 
      days apart, via subcutaneous, intraperitoneal or intramuscular routes with 
      DC/HSV-1 and with mock (DC without virus protein) and positive (alum adjuvanted 
      HSV-1 proteins [HSV-1/ALH]) control vaccines. After measuring anti-HSV-1 antibody 
      levels in blood samples, mice were given live HSV-1 intraperitoneally or via ear 
      pinna to assess the protection level of the vaccines with respect to lethal or 
      latent infection challenge. RESULTS: Intramuscular, but not subcutaneous or 
      intraperitoneal, administration of DC/HSV-1 vaccine provided complete protection 
      against lethal challenge and establishment of latent infection as assessed by 
      death and virus recovery from the trigeminal ganglia. It was also shown that the 
      immunity was not associated with antibody production because DC/HSV-1 vaccine, as 
      opposed to HSV-1/ALH vaccine, produced very little, if any, HSV-1-specific 
      antibody. CONCLUSIONS: Overall, our results may have some impact on the design of 
      vaccines against genital HSV as well as chronic viral infections such as 
      hepatitis B virus, hepatitis C virus and human immunodeficiency virus.
CI  - Copyright (c) 2013 International Society for Cellular Therapy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Ghasemi, Mehdi
AU  - Ghasemi M
AD  - Medical Microbiology Department, Medical School, Karadeniz Technical University, 
      Trabzon, Turkey. ghassemi@gmail.com
FAU - Erturk, Murat
AU  - Erturk M
FAU - Buruk, Kurtulus
AU  - Buruk K
FAU - Sonmez, Mehmet
AU  - Sonmez M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (Antibodies, Viral)
RN  - 0 (Herpes Simplex Virus Vaccines)
RN  - 0 (Viral Envelope Proteins)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - *Antibodies, Viral/immunology/isolation & purification
MH  - Dendritic Cells/*cytology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/metabolism
MH  - Herpes Simplex/virology
MH  - Herpes Simplex Virus Vaccines/administration & dosage/immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Interleukin-4/immunology/metabolism
MH  - Mice
MH  - Simplexvirus/*immunology/pathogenicity
MH  - Viral Envelope Proteins/immunology
EDAT- 2013/04/13 06:00
MHDA- 2013/11/05 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/06/12 00:00 [received]
PHST- 2012/10/07 00:00 [revised]
PHST- 2012/11/11 00:00 [accepted]
PHST- 2013/04/13 06:00 [entrez]
PHST- 2013/04/13 06:00 [pubmed]
PHST- 2013/11/05 06:00 [medline]
AID - S1465-3249(12)00041-2 [pii]
AID - 10.1016/j.jcyt.2012.11.012 [doi]
PST - ppublish
SO  - Cytotherapy. 2013 Mar;15(3):352-61. doi: 10.1016/j.jcyt.2012.11.012.